The Monash Antibody Technologies Facility (MATF) provides services for antibody production, assay development, robotics, high throughput screening and antibody characterisation. We use state-of-the-art equipment to support researchers not only from Monash University but elsewhere in Victoria, Australia and world-wide.
The primary focus for our platform is generating high-affinity monoclonal antibodies through advanced discovery techniques and antibody engineering. However, we are keen to help customers with their antibody or laboratory automation challenges. We are happy to develop new antibody screens and encourage our customers to bring their requests to us.
The staff from MATF work with our customers at every step to ensure the needs of each individual project are met and we are proud to follow a Quality Management System that is certified to ISO9001.
The MATF Platform operates on a fee for services basis for all services and laboratory access.
Using Surface Plasmon Resonance Imaging (SPRi) technology, MATF is able to identify mAbs that bind in a non-competing manner with an antigen suitable for sandwich ELISA development. We can optimise the concentration of each antibody using our high-throughput robotic ELISA platforms. Using the ELISA platform ensures accurate and consistent assessment of the antibody pairs every time.
If you don’t have complementary pairs of antibodies for your ELISA project, MATF can employ the custom antibody service to generate one or both of the antibodies needed.
We can generate between 1-1000mg purified monoclonal antibody from hybridomas generated at MATF or those external to the facility. All cultures must be free from mycoplasma for purification but we can clean up infected cell lines.
Phospho-specific antibody production:
Antibodies directed at phosphorylations sites are critical tools for understanding regulatory mechanisms that control cell signaling, transcription and enzyme activation. MATF can design and produce a phosphorylated and non-phosphorylated peptide and, using our proprietary screening, find binders that specifically recognise the phosphorylation site of interest.
MATF produces hybridoma cell lines expressing monoclonal antibodies against a custom target protein or peptide. The proprietary antigen microarray screening technology selects for large numbers of specific, high affinity, IgG secreting clones. MATF can perform a custom monoclonal production project with as little as 0.4mg of protein or 1mg of peptide. MATF will deliver up to five individual clones and antibody supernatants with a typical production time of 12–16 weeks. Additional services and clones can be supplied on request.
Affinity maturation, antibody humanisation and isotype switching are all available services. Please contact us for more information
Monash Antibody Technologies Facility has not received any reviews.
Monash Antibody Technologies Facility has not received any endorsements.